Ratings by Cantor Fitzgerald (Li Watsek)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/21/2026 | Nuvation Bio Inc | NUVB | New Coverage | Overweight (N/A) |
6.83 (6.74) |
-1.32% | Details | |
| 8/12/2026 | Replimune Group | REPL | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/31/2026 | Replimune Group | REPL | Upgrade | Overweight (Neutral) |
5.41 (15.57) |
187.8% | Details | |
| 7/8/2026 | Immuneering Corporation | IMRX | New Coverage | Overweight (N/A) |
5.10 (4.83) |
-5.29% | Details | |
| 6/22/2026 | Adlai Nortye Ltd. | ANL | New Coverage | Overweight (N/A) |
10.10 (13.91) |
37.72% | Details | |
| 6/9/2026 | Nuvalent | NUVL | Downgrade | Neutral (Overweight) |
88.49 (123.96) |
40.08% | Details | |
| 6/4/2026 | Kura Oncology | KURA | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/4/2026 | Sensei Biotherapeutics | SNSE | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/3/2026 | Ideaya Biosciences | IDYA | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/2/2026 | Nuvalent | NUVL | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/2/2026 | ArriVent BioPharma | AVBP | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/29/2026 | Sensei Biotherapeutics | SNSE | New Coverage | Overweight (N/A) |
17.59 (13.85) |
-21.26% | Details | |
| 5/22/2026 | Ideaya Biosciences | IDYA | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/22/2026 | ArriVent BioPharma | AVBP | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/20/2026 | Protara Therapeutics | TARA | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/15/2026 | Corvus Pharmaceuticals | CRVS | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/17/2026 | Tyra Biosciences | TYRA | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/10/2026 | Replimune Group | REPL | Downgrade | Neutral (Overweight) |
5.91 (5.41) |
-8.46% | Details | |
| 4/1/2026 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/16/2026 | Ideaya Biosciences | IDYA | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/13/2026 | Corvus Pharmaceuticals | CRVS | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/12/2026 | Compass Therapeutics | CMPX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/2/2026 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2026 | Zai Lab | ZLAB | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/18/2026 | Ideaya Biosciences | IDYA | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/12/2026 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 1/23/2026 | Corvus Pharmaceuticals | CRVS | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/16/2026 | ArriVent BioPharma | AVBP | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/12/2026 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/22/2025 | ArriVent BioPharma | AVBP | New Coverage | Overweight (N/A) |
22.01 (30.15) |
36.98% | Details | |
| 12/11/2025 | Corvus Pharmaceuticals | CRVS | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/3/2025 | Compass Therapeutics | CMPX | New Coverage | Overweight (N/A) |
5.22 (2.32) |
-55.56% | Details | |
| 11/26/2025 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/13/2025 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/12/2025 | Replimune Group | REPL | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/4/2025 | Fate Therapeutics | FATE | Maintain | Neutral (Neutral) |
|
Details | ||
| 10/13/2025 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/8/2025 | Arcus Biosciences | RCUS | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/2/2025 | Context Therapeutics | CNTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2025 | Ideaya Biosciences | IDYA | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/27/2025 | Legend Biotech Corp. | LEGN | New Coverage | Overweight (N/A) |
35.08 (31.44) |
-10.38% | Details | |
| 8/8/2025 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/4/2025 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/30/2025 | Replimune Group | REPL | Upgrade | Overweight (Neutral) |
3.75 (5.91) |
57.6% | Details | |
| 7/22/2025 | Replimune Group | REPL | Downgrade | Neutral (Overweight) |
12.32 (15.57) |
26.38% | Details | |
| 6/27/2025 | Kura Oncology | KURA | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/26/2025 | Kura Oncology | KURA | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/25/2025 | Replimune Group | REPL | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/20/2025 | Replimune Group | REPL | New Coverage | Overweight (N/A) |
9.49 (12.32) |
29.82% | Details | |
| 6/12/2025 | Corvus Pharmaceuticals | CRVS | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/3/2025 | Kura Oncology | KURA | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/23/2025 | Kura Oncology | KURA | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/15/2025 | Acrivon Therapeutics Inc | ACRV | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/14/2025 | Affimed Therapeutics | AFMD | Downgrade | Neutral (Overweight) |
0.13 (0.18) |
38.46% | Details | |
| 5/12/2025 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/26/2025 | Acrivon Therapeutics Inc | ACRV | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/14/2025 | Protera Therapeutics | TARA | New Coverage | Overweight (N/A) |
4.02 (3.87) |
-3.73% | Details | |
| 2/25/2025 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/31/2025 | Acrivon Therapeutics Inc | ACRV | New Coverage | Overweight (N/A) |
5.79 (2.06) |
-64.42% | Details | |
| 1/24/2025 | ALX Oncology | ALXO | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/15/2024 | Ideaya Biosciences | IDYA | New Coverage | Overweight (N/A) |
30.47 (39.58) |
29.9% | Details | |
| 6/3/2024 | Bicycle Therapeutics | BCYC | Maintain | Overweight (N/A) |
|
Details | ||
| 10/3/2023 | ALX Oncology | ALXO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/14/2023 | ALX Oncology | ALXO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/11/2023 | ALX Oncology | ALXO | Maintain | Overweight (N/A) |
|
Details | ||
| 6/13/2023 | Aptose Biosciences | APTO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2023 | Corvus Pharmaceuticals | CRVS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/4/2023 | Fate Therapeutics | FATE | Maintain | Neutral (N/A) |
|
Details | ||
| 4/4/2023 | Oncternal Therapeutics | ONCT | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2023 | Fate Therapeutics | FATE | Downgrade | Neutral (Overweight) |
11.00 (2.38) |
-78.36% | Details | |
| 12/22/2022 | Oncternal Therapeutics | ONCT | New Coverage | Overweight (N/A) |
0.88 (0.53) |
-39.77% | Details | |
| 11/9/2022 | ALX Oncology | ALXO | Maintain | Overweight (N/A) |
|
Details | ||
| 11/4/2022 | Fate Therapeutics | FATE | New Coverage | Overweight (N/A) |
19.45 (2.38) |
-87.76% | Details | |
| 11/4/2022 | Corvus Pharmaceuticals | CRVS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/3/2022 | Aptose Biosciences | APTO | Maintain | Overweight (N/A) |
|
Details | ||
| 7/12/2022 | Kura Oncology | KURA | New Coverage | Overweight (N/A) |
17.24 (12.69) |
-26.39% | Details | |
| 4/25/2022 | Nkarta Inc. | NKTX | New Coverage | Neutral (N/A) |
7.77 (2.68) |
-65.51% | Details | |
| 4/7/2022 | Bicycle Therapeutics | BCYC | New Coverage | Overweight (N/A) |
41.76 (4.20) |
-89.94% | Details | |
| 2/23/2022 | Affimed Therapeutics | AFMD | New Coverage | Overweight (N/A) |
4.23 (0.13) |
-96.93% | Details | |
| 7/21/2021 | SELLAS Life Sciences Group | SLS | New Coverage | Overweight (N/A) |
8.60 (13.33) |
55% | Details | |
| 5/27/2021 | Corvus Pharmaceuticals | CRVS | New Coverage | Overweight (N/A) |
2.66 (13.92) |
423.31% | Details |
